Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease

Luca P. Piodi, Maria Teresa Bardella, Cristina Rocchia, Bruno M. Cesana, Annarita Baldassarri, Maurizio Quatrini

Research output: Contribution to journalArticle

Abstract

Goals: To evaluate the prevalence of Helicobacter pylori (Hp) infection in a group of inflammatory bowel disease (IBD) outpatients and the possible influence of treatment. Background: The low prevalence of Hp infection in these patients is usually attributed to environmental factors; the role of drugs has not been fully investigated. Study: Seventy-two consecutive outpatients underwent a C 13-urea breath test for Hp: 32 with Crohn's disease (13 men; mean age, 48 years; range, 20-72 years) and 40 with ulcerative colitis (25 men; mean age, 49 years; range, 25-71 years). Thirty-one patients were treated with sulfasalazine and 41 with 5-ASA. The control group consisted of 72 age- and sex-matched subjects. Results: The prevalence of Hp infection was 47% in the IBD patients and 61% in the controls (p = 0.089; odds ratio = 0.55; 95% CI = 0.283-1.089) with a statistically significant increase for each year of age (p = 0.044; odds ratio = 1.02; 95% CI = 1.001-1.052). Among the IBD patients, age and gender, the type, activity, duration, extent of the disease, or the calendar year of diagnosis, had no influence on Hp infection. H. pylori was detected in 65% of the patients treated with sulfasalazine and in 34% treated with 5-ASA (p = 0.017). Conclusions: Although low, the prevalence of Hp infection in our patients was not significantly different from that in the controls. 5-ASA, and not sulfasalazine, may have a protective effect against Hp infection.

Original languageEnglish
Pages (from-to)22-25
Number of pages4
JournalJournal of Clinical Gastroenterology
Volume36
Issue number1
DOIs
Publication statusPublished - Jan 2003

Fingerprint

Mesalamine
Helicobacter Infections
Inflammatory Bowel Diseases
Helicobacter pylori
Sulfasalazine
Outpatients
Odds Ratio
Breath Tests
Ulcerative Colitis
Crohn Disease
Urea
Control Groups

Keywords

  • 5-Aminosalicylic acid
  • C
  • Helicobacter pylori
  • Inflammatory bowel diseases
  • Sulfasalazine
  • Urea breath test

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. / Piodi, Luca P.; Bardella, Maria Teresa; Rocchia, Cristina; Cesana, Bruno M.; Baldassarri, Annarita; Quatrini, Maurizio.

In: Journal of Clinical Gastroenterology, Vol. 36, No. 1, 01.2003, p. 22-25.

Research output: Contribution to journalArticle

Piodi, Luca P. ; Bardella, Maria Teresa ; Rocchia, Cristina ; Cesana, Bruno M. ; Baldassarri, Annarita ; Quatrini, Maurizio. / Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. In: Journal of Clinical Gastroenterology. 2003 ; Vol. 36, No. 1. pp. 22-25.
@article{aa265cd53bbc4a9ebcd71ef76aa4fa2f,
title = "Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease",
abstract = "Goals: To evaluate the prevalence of Helicobacter pylori (Hp) infection in a group of inflammatory bowel disease (IBD) outpatients and the possible influence of treatment. Background: The low prevalence of Hp infection in these patients is usually attributed to environmental factors; the role of drugs has not been fully investigated. Study: Seventy-two consecutive outpatients underwent a C 13-urea breath test for Hp: 32 with Crohn's disease (13 men; mean age, 48 years; range, 20-72 years) and 40 with ulcerative colitis (25 men; mean age, 49 years; range, 25-71 years). Thirty-one patients were treated with sulfasalazine and 41 with 5-ASA. The control group consisted of 72 age- and sex-matched subjects. Results: The prevalence of Hp infection was 47{\%} in the IBD patients and 61{\%} in the controls (p = 0.089; odds ratio = 0.55; 95{\%} CI = 0.283-1.089) with a statistically significant increase for each year of age (p = 0.044; odds ratio = 1.02; 95{\%} CI = 1.001-1.052). Among the IBD patients, age and gender, the type, activity, duration, extent of the disease, or the calendar year of diagnosis, had no influence on Hp infection. H. pylori was detected in 65{\%} of the patients treated with sulfasalazine and in 34{\%} treated with 5-ASA (p = 0.017). Conclusions: Although low, the prevalence of Hp infection in our patients was not significantly different from that in the controls. 5-ASA, and not sulfasalazine, may have a protective effect against Hp infection.",
keywords = "5-Aminosalicylic acid, C, Helicobacter pylori, Inflammatory bowel diseases, Sulfasalazine, Urea breath test",
author = "Piodi, {Luca P.} and Bardella, {Maria Teresa} and Cristina Rocchia and Cesana, {Bruno M.} and Annarita Baldassarri and Maurizio Quatrini",
year = "2003",
month = "1",
doi = "10.1097/00004836-200301000-00008",
language = "English",
volume = "36",
pages = "22--25",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease

AU - Piodi, Luca P.

AU - Bardella, Maria Teresa

AU - Rocchia, Cristina

AU - Cesana, Bruno M.

AU - Baldassarri, Annarita

AU - Quatrini, Maurizio

PY - 2003/1

Y1 - 2003/1

N2 - Goals: To evaluate the prevalence of Helicobacter pylori (Hp) infection in a group of inflammatory bowel disease (IBD) outpatients and the possible influence of treatment. Background: The low prevalence of Hp infection in these patients is usually attributed to environmental factors; the role of drugs has not been fully investigated. Study: Seventy-two consecutive outpatients underwent a C 13-urea breath test for Hp: 32 with Crohn's disease (13 men; mean age, 48 years; range, 20-72 years) and 40 with ulcerative colitis (25 men; mean age, 49 years; range, 25-71 years). Thirty-one patients were treated with sulfasalazine and 41 with 5-ASA. The control group consisted of 72 age- and sex-matched subjects. Results: The prevalence of Hp infection was 47% in the IBD patients and 61% in the controls (p = 0.089; odds ratio = 0.55; 95% CI = 0.283-1.089) with a statistically significant increase for each year of age (p = 0.044; odds ratio = 1.02; 95% CI = 1.001-1.052). Among the IBD patients, age and gender, the type, activity, duration, extent of the disease, or the calendar year of diagnosis, had no influence on Hp infection. H. pylori was detected in 65% of the patients treated with sulfasalazine and in 34% treated with 5-ASA (p = 0.017). Conclusions: Although low, the prevalence of Hp infection in our patients was not significantly different from that in the controls. 5-ASA, and not sulfasalazine, may have a protective effect against Hp infection.

AB - Goals: To evaluate the prevalence of Helicobacter pylori (Hp) infection in a group of inflammatory bowel disease (IBD) outpatients and the possible influence of treatment. Background: The low prevalence of Hp infection in these patients is usually attributed to environmental factors; the role of drugs has not been fully investigated. Study: Seventy-two consecutive outpatients underwent a C 13-urea breath test for Hp: 32 with Crohn's disease (13 men; mean age, 48 years; range, 20-72 years) and 40 with ulcerative colitis (25 men; mean age, 49 years; range, 25-71 years). Thirty-one patients were treated with sulfasalazine and 41 with 5-ASA. The control group consisted of 72 age- and sex-matched subjects. Results: The prevalence of Hp infection was 47% in the IBD patients and 61% in the controls (p = 0.089; odds ratio = 0.55; 95% CI = 0.283-1.089) with a statistically significant increase for each year of age (p = 0.044; odds ratio = 1.02; 95% CI = 1.001-1.052). Among the IBD patients, age and gender, the type, activity, duration, extent of the disease, or the calendar year of diagnosis, had no influence on Hp infection. H. pylori was detected in 65% of the patients treated with sulfasalazine and in 34% treated with 5-ASA (p = 0.017). Conclusions: Although low, the prevalence of Hp infection in our patients was not significantly different from that in the controls. 5-ASA, and not sulfasalazine, may have a protective effect against Hp infection.

KW - 5-Aminosalicylic acid

KW - C

KW - Helicobacter pylori

KW - Inflammatory bowel diseases

KW - Sulfasalazine

KW - Urea breath test

UR - http://www.scopus.com/inward/record.url?scp=0037213969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037213969&partnerID=8YFLogxK

U2 - 10.1097/00004836-200301000-00008

DO - 10.1097/00004836-200301000-00008

M3 - Article

C2 - 12488702

AN - SCOPUS:0037213969

VL - 36

SP - 22

EP - 25

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 1

ER -